Peptide Schedule
Dulaglutide (Trulicity)30 residuesHGEGTFTSDVSSYLEGQAAKEFIAWLVKGREach bubble = one amino acid. Size = residue mass. Color = chemical class.

Dulaglutide (Trulicity) Dosage Calculator

Weight LossInjectionFDA Approved~5 days half-life

Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist manufactured by Eli Lilly for the treatment of type 2 diabetes and reduction of major adverse cardiovascular events.

FDA-approved for type 2 diabetes with proven glycemic controlReduces major adverse cardiovascular events (REWIND trial: HR 0.88)Convenient once-weekly pre-filled pen — no reconstitution requiredDose-dependent HbA1c reductions of 1.0-1.6% across AWARD trials

0.75mcg · Weekly

100500
0.0 units
100 units (1mL)
Concentration
0
mcg/mL
Draw Volume
< 0.001
mL
Syringe Units
< 0.1
units
Doses / Vial
0
doses

Summary: Add 0mL BAC water to your 0.75mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.75mcg dose. This vial will last 0 doses.

Cycle Planner

Subcutaneous. Typical beginner frequency: weekly.

Dulaglutide (Trulicity) Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~5 days (120 hours)
50%25%12.5%100%75%50%25%0%05d10d15d20d25dTime after injectionDose remaining
After 1 half-life (5d): 50% remainsAfter 2 half-lives (10d): 25% remainsAfter 3 half-lives (15d): 12.5% remains
At a 1.5mcg dose: 50% = 1mcg remaining after 5d. Recommended frequency: Weekly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Dulaglutide (Trulicity) Dosing Protocol

LevelDose / InjectionFrequency
Beginner0.75mgWeekly
Moderate1.5mgWeekly
Aggressive4.5mgWeekly

Note: FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction. Delivered via pre-filled single-use pen (Trulicity). Titrate from 0.75mg weekly; may increase every 4 weeks. Max dose 4.5mg/week.

About Dulaglutide (Trulicity)

Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist manufactured by Eli Lilly for the treatment of type 2 diabetes and reduction of major adverse cardiovascular events. It is a fusion protein consisting of two GLP-1 analog sequences linked to a modified human IgG4 Fc domain, giving it a molecular weight of approximately 63 kDa and a half-life of about 5 days. This allows convenient once-weekly dosing via a pre-filled, single-use pen. The REWIND trial demonstrated a 12% reduction in major cardiovascular events over a median 5.4-year follow-up, making it the first GLP-1 agonist to show cardiovascular benefit in a population with and without established cardiovascular disease.

Frequently Asked Questions